Q

Qualigen Therapeutics
D

QLGN

4.88000
USD
0.00
(0.00%)
Pre Open
Volume
600
EPS
-6
Div Yield
-
P/E
0
Market Cap
3,593,783
OverviewSignalsIdeasNews
Related Instruments
    A
    ARCT
    -2.310
    (-12.60%)
    16.020 USD
    B
    BGNE
    -4.220
    (-2.18%)
    189.320 USD
    C
    CRIS
    -0.04000
    (-1.00%)
    3.96000 USD
    I
    IMGN
    0
    (0%)
    0.000000 USD
    M
    MGNX
    -0.23000
    (-6.04%)
    3.58000 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    T
    TGTX
    -1.325
    (-4.30%)
    29.515 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    More
News

Title: Qualigen Therapeutics Inc

Sector: Healthcare
Industry: Biotechnology
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.